Tonix Pharmaceuticals (NASDAQ:TNXP) Rating Lowered to Sell at Wall Street Zen

Tonix Pharmaceuticals (NASDAQ:TNXP) was downgraded by investment analysts at Wall Street Zen from a “hold” rating to a “sell” rating in a research report issued to clients and investors on Saturday.

Separately, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Tonix Pharmaceuticals in a research note on Wednesday, January 21st. One equities research analyst has rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, the company has an average rating of “Hold”.

Tonix Pharmaceuticals Price Performance

Shares of TNXP opened at $12.88 on Friday. The company has a 50-day simple moving average of $15.42 and a two-hundred day simple moving average of $17.91. The firm has a market capitalization of $172.59 million, a PE ratio of -0.90 and a beta of 1.88. Tonix Pharmaceuticals has a one year low of $12.70 and a one year high of $69.97.

Tonix Pharmaceuticals (NASDAQ:TNXP) last posted its earnings results on Thursday, March 12th. The company reported ($3.98) earnings per share for the quarter, missing analysts’ consensus estimates of ($3.16) by ($0.82). The firm had revenue of $5.39 million for the quarter, compared to analysts’ expectations of $2.97 million. Tonix Pharmaceuticals had a negative return on equity of 60.15% and a negative net margin of 946.22%. Analysts expect that Tonix Pharmaceuticals will post -1762.5 EPS for the current fiscal year.

Insider Buying and Selling

In other Tonix Pharmaceuticals news, CEO Seth Lederman bought 15,000 shares of the business’s stock in a transaction on Wednesday, March 18th. The shares were acquired at an average cost of $14.89 per share, for a total transaction of $223,350.00. Following the purchase, the chief executive officer owned 15,001 shares in the company, valued at approximately $223,364.89. This trade represents a 1,500,000.00% increase in their position. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Corporate insiders own 0.03% of the company’s stock.

Institutional Inflows and Outflows

Hedge funds have recently modified their holdings of the business. Royal Bank of Canada purchased a new stake in shares of Tonix Pharmaceuticals during the first quarter valued at $610,000. Geode Capital Management LLC raised its position in Tonix Pharmaceuticals by 182.4% in the 2nd quarter. Geode Capital Management LLC now owns 175,212 shares of the company’s stock worth $6,305,000 after buying an additional 113,175 shares during the last quarter. Police & Firemen s Retirement System of New Jersey purchased a new position in Tonix Pharmaceuticals in the 2nd quarter worth about $62,000. JPMorgan Chase & Co. bought a new position in Tonix Pharmaceuticals during the 2nd quarter valued at about $129,000. Finally, Legal & General Group Plc purchased a new stake in shares of Tonix Pharmaceuticals during the 2nd quarter valued at about $25,000. Hedge funds and other institutional investors own 82.26% of the company’s stock.

Key Headlines Impacting Tonix Pharmaceuticals

Here are the key news stories impacting Tonix Pharmaceuticals this week:

• Positive Sentiment: First participant dosed in a Phase 1 investigator‑initiated pharmacodynamic study of TNX‑1900 to assess potential for treating migraine and craniofacial pain; intranasal oxytocin blocks CGRP release in animal models and represents a mechanism distinct from current CGRP drugs, which could broaden Tonix’s pipeline if signals are positive. Tonix Pharmaceuticals Announces First Participant Dosed in Phase 1 Investigator-Initiated Pharmacodynamic Study of TNX-1900
• Neutral Sentiment: Multiple outlets (Business Insider, Yahoo Finance, TipRanks) picked up the dosing announcement — that raises visibility and investor attention but the study is early‑stage (pharmacodynamic model), so clinical readouts and commercialization remain uncertain. Tonix Pharmaceuticals Announces First Participant Dosed (Business Insider)
• Negative Sentiment: Zacks Research substantially lowered its near‑term EPS forecasts for Tonix, cutting FY2026 and FY2027 estimates and issuing much larger expected losses per share (e.g., FY2026 now modeled at roughly -$10.52). Those revisions signal analyst concern about cash runway, development timelines and the likelihood of future dilution — a key reason for downward pressure on the stock. What is Zacks Research’s Estimate for TNXP FY2028 Earnings?

About Tonix Pharmaceuticals

Tonix Pharmaceuticals is a clinical-stage biotechnology company focused on developing therapeutics for central nervous system disorders, immunology and rare diseases. The company’s pipeline includes small-molecule and biologic product candidates designed to address conditions such as fibromyalgia, post-traumatic stress disorder (PTSD) and other chronic pain syndromes, as well as vaccines for potential viral and biothreat agents.

Among Tonix’s lead programs is TNX-102 SL, a sublingual formulation of cyclobenzaprine being evaluated for the treatment of fibromyalgia and PTSD.